Careers Contact
Careers Contact

AI-Immunology™

Evaxion’s pioneering AI-Immunology™ platform accelerates fast and effective vaccine target discovery, design, and development. Using the power of AI, our platform simulates the human immune system and generates predictive models to identify and develop personalized and other next-generation immunotherapies for patients.

About AI-Immunology™

Evaxion is a pioneering TechBio company with a leading AI–platform, AI-Immunology™, for fast and effective vaccine target discovery, design and development. AI-Immunology™ is clinically validated and can identify therapeutically relevant vaccine targets for cancer and infectious diseases.

AI-Immunology™ allows for ground-breaking development of novel personalized and precision vaccines for cancer and infectious diseases. The platform consists of a collection of unique in-house developed AI building blocks that can be intelligently combined to generate tailored AI prediction models addressing complex immune-related healthcare issues.

The power of AI-Immunology™ in vaccine target discovery, design and development

0

clinical trials confirm predictive capabilities and link to outcomes

0HRS

to complete target discovery

0%

fewer targets needs testing

0%+

on average cheaper target discovery versus reverse vaccinology

0%

vaccine target hit-rate

0

different modalities (protein, DNA, mRNA, peptides)

0+

different diseases can be addressed

Learn more about AI-Immunology™

AI-Immunology™ – A Leading AI Platform
Watch Andreas Holm Mattsson, Chief AI Officer and Founder of Evaxion, provide an introduction to the company’s history and the driving force behind the development of our core AI-Immunology™ platform. In this video, you will gain new insights into the scalable modular architecture of AI-Immunology™ and how it has enabled the company to expand to different therapeutic areas.
EvaxMHC 4.0 – A Cutting-Edge AI Building Block
Watch Michael Schantz Klausen, Scientist and ML Engineer at Evaxion, give a presentation on EvaxMHC – one of the core building blocks of our AI-Immunology™ platform. In his presentation, Michael takes you through the intricacies of peptide-MHC interactions and how EvaxMHC novel deep-learning algorithms achieve best-in-class performance.
Addressing difficult to treat cancers with AI-Immunology™
Watch Jens Kringelum, VP of AI & Innovation at Evaxion, give a presentation on how Evaxion is addressing difficult to treat cancers with AI-Immunology™

About PIONEER™

PIONEER™ is a proprietary AI-Immunology™ model for the rapid discovery of patient-specific neoantigens used for our personalized cancer immunotherapies. We want to challenge and improve the standardized therapies of today, where one size fits all, risking unspecific immune activation. With our AI-Immunology™ platform, we seek out and target cancer cells, creating truly personalized therapies where one size fits one and only one.

About ObsERV™

ObsERV™ is a proprietary AI-Immunology™ model that rapidly can be used in personalized cancer immunotherapies to complement neoantigens. We have developed a bioinformatics model that can identify endogenous retrovirus (ERVs) based on sequencing data and design a personalized ERV antigen treatment. We have proof of concept that our method works in preclinical models.

About EDEN™

EDEN™ is a proprietary AI-Immunology™ model that rapidly identifies vaccine targets – the parts of a pathogen – that can trigger a sufficient immune response. With EDEN™, we are able to identify the most protective vaccine targets of pathogens faster and at a lower cost than current state-of-the-art methods. This is a novel approach to vaccine development and holds the  potential to combat the rising global issue of bacterial antibiotic resistance and viral strain divergence.

About RAVEN™

RAVEN™ is a proprietary AI-Immunology™ model that rapidly identifies vaccine candidates against existing, emerging, and mutating viral diseases. We are developing next-generation vaccine candidates that aim to trigger a potent B- and T-cell response simultaneously. Current vaccines against viral disease are challenged by fading efficacy and evasion by mutating viruses. With RAVEN™, the addition of the T-cell component is designed to secure a broader, more durable protection.